All News
Filter News
Found 2,896 articles
-
MilliporeSigma Receives First U.S. Patent for Improved CRISPR Genome-Editing Method
2/19/2019
Proxy-CRISPR technology provides solution to improve genome editing and advance new possibilities for research
-
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
2/19/2019
Through this agreement, the companies aim to discover optimized NAM-NK cells that could be used to improve the treatment of hematologic malignancies and solid tumors.
-
Caribou Biosciences Announces Expansion of Scientific Advisory Board
2/12/2019
The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.
-
Immigrant Scientists Lead Charge in Understanding Human Biology and Disease - February 7, 2019
2/7/2019
$250,000 in Vilcek Foundation Prizes awarded to Angelika Amon, Amit Choudhary, Jeanne T. Paz, and Mikhail G. Shapiro
-
IDT backs innovative synthetic biology start-ups with grant awards
2/7/2019
Demonstrating its commitment to advocating for synthetic biology research, Integrated DNA Technologies’ (IDT) Synthetic Biology Start-up Grant Program has once again benefited innovative start-ups in their missions to impact sustainable manufacturing, human health, and/or humanitarian causes. T
-
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
-
The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.
-
Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results
2/5/2019
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2018 and provided full-year 2019 financial guidance.
-
Immigrant Scientists Lead Charge in Understanding Human Biology and Disease
2/4/2019
$250,000 in Vilcek Foundation Prizes awarded to Angelika Amon, Amit Choudhary, Jeanne Paz, and Mikhail Shapiro
-
QPS Expands Translational Medicine Unit Three-Fold to Increase Support for Biopharmaceutical, Biotechnology and CRO Partners, Address Market Demand for Gene Therapy
2/4/2019
On the heels of recent FDA approvals of gene therapies in the US market, QPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, today announced a three-fold expansion of its U.S.-based Translational Medicine division, which supports nucleic acid therapeutics.
-
It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup...
-
Repare Therapeutics Announces a Strategic Partnership Agreement With ONO Pharmaceutical Co., Ltd. for Repare’s Polθ Inhibitor Program in Japan and Selected Territories in Asia
1/31/2019
Repare Therapeutics, Inc. announced that it has entered into an exclusive strategic research, development and commercialization partnership with ONO Pharmaceutical Co., Ltd., for Repare’s small molecule Polθ inhibitor program in Japan, South Korea, Taiwan, Hong Kong, Macau and ASEAN countries, excluding mainland China.
-
CARDIOREG Alliance: ZeClinics and Taros to Develop New Heart Regeneration Therapies
1/30/2019
Zeclinics SL and Taros Chemicals GmbH join forces to develop novel therapies for the treatment of ischemic heart disease, representing the leading cause of death worldwide.
-
Horizon Discovery and Rutgers University Form Exclusive Partnership to Develop Next Generation Novel Gene Editing Technology
1/28/2019
Horizon will work with Rutgers University to develop and commercialise base editing platform for therapeutic and research applications
-
BioSpace Movers and Shakers: Jan. 25
1/25/2019
Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more. -
The 2019 Co-located Phacilitate Leaders World & World Stem Cell Summit in Miami Solidified Regenerative Medicine as the Future of Healthcare
1/25/2019
The international regenerative medicine community concluded a week of sharing breakthroughs, facing challenges and developing collaborations at the 2019 co-locatedPhacilitate Leaders World and World Stem Cell Summit (WSCS) at the Hyatt Regency Miami, January 22-25, 2019.
-
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
1/24/2019
Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas
-
CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies
1/23/2019
CAMBRIDGE and BOSTON, Mass. and BERLIN, Germany, January 22, 2019 / CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and ProBioGen, a premier German service and technology provider, today announced a multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise.
-
AgeX Therapeutics’ CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019
1/22/2019
AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that Founder and CEO Michael D. West, Ph.D. presented at Precision Medicine World Conference 2019, January 21 in Silicon Valley.
-
Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients
1/21/2019
In preclinical models, implants of PEC-Direct (also known as VC-02) are capable of forming a functional beta cell mass that controls blood glucose levels